Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
bristol-myers squibb
life sciences
national
national blog main
novartis
acquisition
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
cancer
cancer immunotherapy
celgene
detroit blog main
detroit top stories
fda
immunotherapy
indiana blog main
indiana top stories
m&a
manufacturing
national top stories
new york blog main
new york top stories
plan
raleigh-durham blog main
raleigh-durham top stories
samit hirawat
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
scott gottlieb
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
What
celgene
5
×
acquisition
anniversary
approaches
bn
bristol
chief
clinical
company’s
corporation
diversity
hirawat
medical
medicine
myers
myers’s
officer
pipeline
progress
scrip
spoke
squibb
trial
year
airport
annual
apocalypse
beds
bio
biopharma
biopharmaceutical
called
car
cells
celularity
colleagues
company
creating
days
derived
Language
unset
Current search:
celgene
×
@xconomy.com
3 years ago
Bristol Myers’s Hirawat on Pipeline Progress, Clinical Trial Diversity
@xconomy.com
3 years ago
Bristol Myers’s Hirawat on Pipeline Progress, Clinical Trial Diversity
@xconomy.com
5 years ago
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More
@xconomy.com
5 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More
@techcrunch.com
6 years ago
With $250 million, Peter Diamandis’ new startup is all about taking stem cells from placentas
